LTRN

Lantern Pharma Inc. (LTRN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. Lantern Pharma Inc. is an artificial intelligence (A.I.) focused biopharmaceutical company developing cancer therapies. The company utilizes its proprietary RADR® platform to identify drug candidates and patient populations. The portfolio includes three clinical-stage oncology candidates (LP-300, LP-184/STAR-001, LP-284) and an Antibody Drug Conjugate (ADC) program. The company is classified as a Smaller Reporting Company and an Emerging Growth Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by approximately 16% in Q3 2025 compared to Q3 2024 ($4.35M vs. $5.18M). This was driven primarily by a 34% decrease in Research and Development (R&D) expenses ($2.44M vs. $3.72M), attributed to reduced spending on research studies, materials, and payroll. Conversely, General and Administrative (G&A) expenses increased by 31% ($1.91M vs. $1.46M) due to higher business development, investor relations, and professional fees.
• Net Loss: The net loss narrowed by approximately 7% in Q3 2025 compared to the prior year quarter, reflecting the reduction in operating costs.
• Investing Activities: Net cash provided by investing activities turned positive at $12.76M for the nine months ended Sept 30, 2025, compared to a net use of $78k in the prior year period. This shift was due to significant net redemptions of marketable securities ($23.3M redemptions vs. $10.5M purchases).
• Financing Activities: The company raised approximately $972k in financing activities YTD 2025, primarily through an "at-the-market" (ATM) offering, compared to $67k in the prior year period.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management states that current cash, cash equivalents, and marketable securities (~$12.4M) are sufficient to fund operations until approximately late June 2026 to mid-August 2026. The filing explicitly notes that these factors raise substantial doubt about the company's ability to continue as a going concern without obtaining substantial additional funding.
• Capital Strategy: The company entered into an ATM Sales Agreement in July 2025 to sell up to $15.53M of common stock. As of the report date, they had sold shares for gross proceeds of approximately $1.62M (including post-quarter sales).
• Development Progress:
  • LP-300: Advancing in the Harmonic™ Phase 2 trial for non-small cell lung cancer (NSCLC).
  • LP-184 (STAR-001): Phase 1a enrollment completed; development plans for CNS indications are being optimized.
  • LP-284: Advancing in Phase 1 clinical trial for hematological cancers.
• Risks: Key risks include the inability to secure funding, failure of clinical trials, reliance on third-party manufacturers, and the impact of trade policies/tariffs on operations. The company also noted a stock option repricing in September 2025, resulting in incremental compensation expense.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projected runway (late June to mid-August 2026) given the current burn rate and potential for increased clinical trial costs.
• ATM Utilization: Monitor the pace of share sales under the ATM agreement and the resulting dilution to existing shareholders.
• Clinical Milestones: Confirm upcoming data readouts or enrollment targets for the LP-300 Phase 2 trial and LP-184 Phase 1a follow-up studies.
• Going Concern Status: Review the "Liquidity and Going Concern" note (Note 2) for any updates on the company's ability to raise capital before the projected cash depletion date.
• Stock-Based Compensation: Assess the impact of the recent stock option repricing on future quarterly expenses.